Spots Global Cancer Trial Database for A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
Official Title: A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
Study ID: NCT02958410
Interventions
Study Description
Brief Summary: The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of lymphocyte derived malignancies.
Detailed Description: CD30 is originally described as a marker of Hodgkin's and Reed-Sternberg cells in Hodgkin's lymphoma. CD30 antibody has been applied to treat lymphocyte derived malignancies. To explore the potency of CD30 in CAR-T therapy, this trial is designed and conducted to test the safety and effect of CD30-targeted CAR-T.
Eligibility
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China
Contact Details
Name: Cheng Qian, MD, PhD
Affiliation: Biotherapy Center of Southwest Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
